These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 12641859)

  • 21. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 22. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
    Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
    Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.
    Forbes ML; Hall CB; Jackson A; Masaquel AS; Mahadevia PJ
    J Med Econ; 2010 Mar; 13(1):136-41. PubMed ID: 20128663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
    Neovius K; Buesch K; Sandström K; Neovius M
    Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 28. Palivizumab: a debate about funding.
    Fitzgerald DA; Isaacs D; Tobin B
    J Paediatr Child Health; 2012 May; 48(5):373-7. PubMed ID: 22296413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccines for neonatal viral infections: towards a live respiratory syncytial virus vaccine:a study in risk.
    McIntosh ED; Malinoski FJ; Randolph VB
    Expert Rev Vaccines; 2004 Aug; 3(4):353-7. PubMed ID: 15270633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants.
    Leader S; Yang H; DeVincenzo J; Jacobson P; Marcin JP; Murray DL
    Value Health; 2003; 6(2):100-6. PubMed ID: 12641860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention of respiratory syncytial virus infection in a peripheral hospital: economic problems and ethical questions].
    Faverge B; Bonein M; Attou D; Benskhria S; Gratecos L
    Arch Pediatr; 2000 Apr; 7(4):429. PubMed ID: 10793937
    [No Abstract]   [Full Text] [Related]  

  • 33. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Levin MJ; Hall CB; Long CE; Rodriguez WJ; Arrobio J; Meissner HC; Fulton DR; Welliver RC
    N Engl J Med; 1993 Nov; 329(21):1524-30. PubMed ID: 8413475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico.
    Salinas-Escudero G; Martínez-Valverde S; Reyes-López A; Garduño-Espinosa J; Muñoz-Hernández O; Granados-García V; Rely K
    Salud Publica Mex; 2012; 54(1):47-59. PubMed ID: 22286828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: a cost-effectiveness analysis.
    Rodríguez SP; Fariña D; Bauer G
    Pediatr Infect Dis J; 2008 Jul; 27(7):660-1. PubMed ID: 18520447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The critical role of population-based epidemiology in cost-effectiveness research.
    Joffe S; Lieu TA; Escobar GJ
    Pediatrics; 2000 Apr; 105(4 Pt 1):862-3. PubMed ID: 10742335
    [No Abstract]   [Full Text] [Related]  

  • 37. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations.
    Rackham OJ; Thorburn K; Kerr SJ
    Cardiol Young; 2005 Jun; 15(3):251-5. PubMed ID: 15865826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany.
    Liese JG; Grill E; Fischer B; Roeckl-Wiedmann I; Carr D; Belohradsky BH;
    Eur J Pediatr; 2003 Apr; 162(4):230-6. PubMed ID: 12647195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.